Technical Analysis for BCEL - Atreca, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.15 | -11.76% | -0.02 |
BCEL closed down 11.76 percent on Monday, March 18, 2024, on 6 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 27
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | -11.76% | |
Lower Bollinger Band Walk | Weakness | -11.76% | |
Wide Bands | Range Expansion | -11.76% | |
Lower Bollinger Band Touch | Weakness | -11.76% | |
Oversold Stochastic | Weakness | -11.76% | |
Wide Bands | Range Expansion | -24.62% | |
Gapped Up | Strength | -24.62% | |
Oversold Stochastic | Weakness | -24.62% |
Alert | Time |
---|---|
Possible Inside Day | about 19 hours ago |
Up 10% | about 19 hours ago |
60 Minute Opening Range Breakout | about 22 hours ago |
Up 5% | about 22 hours ago |
Up 3% | about 23 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/27/2024
Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Immunology Solid Tumors Immune System Antibodies Tumor Cancer Immunotherapy Drug Discovery Monoclonal Antibody Antibody Glycoproteins Immune Response Immunotherapeutics Agenus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Immunology Solid Tumors Immune System Antibodies Tumor Cancer Immunotherapy Drug Discovery Monoclonal Antibody Antibody Glycoproteins Immune Response Immunotherapeutics Agenus
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.35 |
52 Week Low | 0.1023 |
Average Volume | 9,799,813 |
200-Day Moving Average | 0.45 |
50-Day Moving Average | 0.25 |
20-Day Moving Average | 0.24 |
10-Day Moving Average | 0.20 |
Average True Range | 0.03 |
RSI (14) | 32.43 |
ADX | 27.79 |
+DI | 14.60 |
-DI | 28.10 |
Chandelier Exit (Long, 3 ATRs) | 0.24 |
Chandelier Exit (Short, 3 ATRs) | 0.25 |
Upper Bollinger Bands | 0.34 |
Lower Bollinger Band | 0.15 |
Percent B (%b) | 0.02 |
BandWidth | 79.46 |
MACD Line | -0.03 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0113 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.21 | ||||
Resistance 3 (R3) | 0.22 | 0.20 | 0.20 | ||
Resistance 2 (R2) | 0.20 | 0.19 | 0.20 | 0.20 | |
Resistance 1 (R1) | 0.18 | 0.18 | 0.17 | 0.17 | 0.19 |
Pivot Point | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 |
Support 1 (S1) | 0.14 | 0.15 | 0.13 | 0.13 | 0.11 |
Support 2 (S2) | 0.12 | 0.14 | 0.12 | 0.10 | |
Support 3 (S3) | 0.10 | 0.12 | 0.10 | ||
Support 4 (S4) | 0.09 |